Evidence map›Paper›PMID 42789109›Full record

ReviewSeminars in immunopathology2026

Thymic function as a central determinant of immune competence and clinical outcomes.

Alessio Taviani, Shirley Genah, Angelica Mancusi, Carmen Dolores De Luca, Marco Rosichini, Franco Locatelli, Enrico Velardi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Seminars in immunopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alessio TavianiPediatric Hematology and Oncology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Shirley GenahPediatric Hematology and Oncology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Angelica MancusiPediatric Hematology and Oncology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Carmen Dolores De LucaPediatric Hematology and Oncology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Marco RosichiniImmunotherapy Integrated Research Center, Division of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Franco LocatelliPediatric Hematology and Oncology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Enrico VelardiPediatric Hematology and Oncology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy. enrico.velardi@opbg.net.ORCID http://orcid.org/0000-0001-8383-0453

Funding

AIRC Special Program Metastatic disease: the key unmet need in oncology 5 per mille 2018 21147Ministero della Salute RF-2016-02364388Ministero dell'Istruzione, dell'Universit. e della Ricerca WC8499_004
6 · The paper itself

Abstract

The thymus is a central regulator of immune competence, sustaining the continuous generation of a diverse and self-tolerant T-cell repertoire throughout life. Although traditionally regarded as primarily relevant during early development, accumulating evidence highlights its persistent role in shaping adaptive immunity across physiological and pathological conditions. In this review, we examine the role of thymic function as a determinant of immune competence and treatment efficacy across conditions in which adaptive immunity is challenged or therapeutically reshaped, including hematopoietic cell transplantation, severe infections, autoimmune diseases, immune checkpoint inhibitor therapy, and aging. In these contexts, impaired thymic activity is consistently associated with contraction of the naïve T‑cell pool, reduced T‑cell receptor (TCR) diversity, increased susceptibility to immune‑related complications, and inferior clinical outcomes. We then provide a critical overview of the methodologies currently available to assess thymic function, including flow-cytometric identification of recent thymic emigrants, molecular quantification of T‑cell receptor excision circles, analysis of TCR repertoire diversity, and imaging‑based approaches, highlighting their respective strengths, limitations, and translational applicability. Finally, we discuss the emerging relevance of thymic function in the context of adaptive and T‑cell-redirecting therapies, where sustained immune competence depends on the integrity of endogenous T‑cell regeneration. Collectively, this review positions thymic function as a clinically actionable biomarker for immune monitoring, patient stratification, and personalization of adaptive immunotherapies.

Indexed as

Thymus GlandAdaptive ImmunityAnimalsBiomarkersHumansReceptors, Antigen, T-CellT-LymphocytesT-Lymphocyte SubsetsTreatment OutcomeBiomarkersReceptors, Antigen, T-CellHematopoietic cell transplantationimmune monitoringImmune reconstitutionImmunotherapyThymus

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.